Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study.
Aussedat G, Maucort-Boulch D, Rey P, Safar V, Karlin L, Elsensohn MH, Bachy E, Lebras L, Favier B, Vantard N, Ghergus D, Golfier C, Sesques P, Lazareth A, Lequeu H, Ferrant E, Salles G, Nicolas-Virelizier E, Ghesquieres H. Aussedat G, et al. Among authors: ghergus d. Leuk Lymphoma. 2022 Mar;63(3):599-607. doi: 10.1080/10428194.2021.1998483. Epub 2021 Oct 31. Leuk Lymphoma. 2022. PMID: 34720034
Refractory diffuse large B-cell lymphoma after first-line immuno-CT: Treatment options and outcomes.
Filliatre-Clement L, Maucort-Boulch D, Bourbon E, Karlin L, Safar V, Bachy E, Sesques P, Ferrant E, Bouafia F, Lazareth A, Ghergus D, Coiffier B, Traverse Glehen A, Salles G, Ghesquieres H, Sarkozy C. Filliatre-Clement L, et al. Among authors: ghergus d. Hematol Oncol. 2018 May 2. doi: 10.1002/hon.2512. Online ahead of print. Hematol Oncol. 2018. PMID: 29722049
Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified.
Bourbon E, Maucort-Boulch D, Fontaine J, Mauduit C, Sesques P, Safar V, Ferrant E, Golfier C, Ghergus D, Karlin L, Lazareth A, Bouafia F, Pica GM, Orsini-Piocelle F, Rocher C, Gros FX, Parrens M, Dony A, Rossi C, Ghesquières H, Bachy E, Traverse-Glehen A, Sarkozy C. Bourbon E, et al. Among authors: ghergus d. Blood Adv. 2021 Aug 24;5(16):3227-3239. doi: 10.1182/bloodadvances.2021004515. Blood Adv. 2021. PMID: 34427583 Free PMC article.
Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
Sesques P, Ferrant E, Safar V, Wallet F, Tordo J, Dhomps A, Karlin L, Brisou G, Vercasson M, Hospital-Gustem C, Schwiertz V, Ranchon F, Rioufol C, Choquet M, Sujobert P, Ghergus D, Bouafia F, Golfier C, Lequeu H, Lazareth A, Novelli S, Devic P, Traverse Glehen A, Viel S, Venet F, Mialou V, Hequet O, Chauchet A, Arkam Y, Nicolas-Virelizier E, Peyrade F, Cavalieri D, Ader F, Ghesquières H, Salles G, Bachy E. Sesques P, et al. Among authors: ghergus d. Am J Hematol. 2020 Nov;95(11):1324-1333. doi: 10.1002/ajh.25951. Epub 2020 Aug 25. Am J Hematol. 2020. PMID: 32744738 Free article. Clinical Trial.
Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
Sesques P, Tordo J, Ferrant E, Safar V, Wallet F, Dhomps A, Brisou G, Bouafia F, Karlin L, Ghergus D, Golfier C, Lequeu H, Lazareth A, Vercasson M, Hospital-Gustem C, Schwiertz V, Choquet M, Sujobert P, Novelli S, Mialou V, Hequet O, Carras S, Fouillet L, Lebras L, Guillermin Y, Leyronnas C, Cavalieri D, Janier M, Ghesquières H, Salles G, Bachy E. Sesques P, et al. Among authors: ghergus d. Clin Nucl Med. 2021 Aug 1;46(8):627-634. doi: 10.1097/RLU.0000000000003756. Clin Nucl Med. 2021. PMID: 34115706
HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma.
Bourbon E, Sesques P, Gossez M, Tordo J, Ferrant E, Safar V, Wallet F, Aussedat G, Maarek A, Bouafia F, Karlin L, Ghergus D, Golfier C, Lequeu H, Lazareth A, Schwiertz V, Viel S, Idlhaj M, Ghesquières H, Monneret G, Bachy E, Venet F. Bourbon E, et al. Among authors: ghergus d. Blood Adv. 2023 Mar 14;7(5):744-755. doi: 10.1182/bloodadvances.2021006563. Blood Adv. 2023. PMID: 35439292 Free PMC article.
Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer.
Sadras T, Martin M, Kume K, Robinson ME, Saravanakumar S, Lenz G, Chen Z, Song JY, Siddiqi T, Oksa L, Knapp AM, Cutler J, Cosgun KN, Klemm L, Ecker V, Winchester J, Ghergus D, Soulas-Sprauel P, Kiefer F, Heisterkamp N, Pandey A, Ngo V, Wang L, Jumaa H, Buchner M, Ruland J, Chan WC, Meffre E, Martin T, Müschen M. Sadras T, et al. Among authors: ghergus d. Mol Cell. 2021 May 20;81(10):2094-2111.e9. doi: 10.1016/j.molcel.2021.03.043. Epub 2021 Apr 19. Mol Cell. 2021. PMID: 33878293 Free PMC article.
End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy.
Sesques P, Karlin L, Massy E, Maarek A, Aussedat G, Lazareth A, Golfier C, Bouafia-Sauvy F, Lequeu H, Ghergus D, Safar V, Ferrant E, Bachy E, Ghesquières H, Confavreux CB, Demangel D, Perrial E, Dumontet C. Sesques P, et al. Among authors: ghergus d. Front Oncol. 2024 Oct 31;14:1436587. doi: 10.3389/fonc.2024.1436587. eCollection 2024. Front Oncol. 2024. PMID: 39544298 Free PMC article.
Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital.
Lan CL, Belot A, Golfier C, Audin B, Sesques P, Bernier A, Safar V, Ferrant E, Lazareth A, Lequeu H, Karlin L, Ghergus D, Maarek A, Aussedat G, Idlhaj M, Salles G, Cherblanc F, Bachy E, Ghesquieres H. Lan CL, et al. Among authors: ghergus d. Hematol Oncol. 2024 Jul;42(4):e3297. doi: 10.1002/hon.3297. Hematol Oncol. 2024. PMID: 38989917 No abstract available.
11 results